当前位置：   首页 > 需求大厅

具体要求： 1、CAS号：1447317-08-9   2、需求量：10-20g  3、结构式见附件，请报价！   [更多]

寻人查找一份日本药品通用名和中文药物名、英文名对照的数据表，要求内容权威可信，信息及时更新（最新），药品包含全面，经核实后内容准确的，可获得200元。具体要求如下 1：以日本药品为准，包含绝大部分药物（如在日本上市，注册，等），药物全面，且错误率在1%以下。 2：不能简单的在百度中下载文件来充数；因为不做处理，这些文件质量上还达不到要求。 3：所谓的药品名都是指的药品通用名，不是商品名，或者化学成份名称。 如果只有日文中文对照或者日文英文对照，即可获得100元。   [更多]

有新药证书的口服单品种的批件转让，具体的先联系后在详谈。   [更多]

破壁灵芝孢子粉 寻找这个保健品的批文 需要投稿者提供转让批文者的联系方式、联系人、以及批文的价格。   [更多]

标题：求购药品批件 需求名称：中药、化药都可，批文。生产线。 和我联系,QQ；1270517234   [更多]

需求药物研发中心质量管理体系文件，至少包含目录及管理制度(数据，记录，仪器，物料，计算机等)   [更多]

各位智友：本人因检测需要，求分享欧洲药典10.0检测 General Chapters部分。应包括以下内容 2.2.32. Loss on drying 2.4.16. Total ash 2.8.1 Ash insoluble in hydrochloric acid 2.8.2 FOREIGN MATTER 2.2.13 WATER 2.8.4 SWELLING INDEX 2.8.15 BITTERNESS VALUE Appendix XI B1. Ethanol-soluble Extractive Appendix XI B2. Water-soluble Extractive   [更多]

本人由于研发需要，现想求购全套中药材生产基地信息，如果可以提供全套信息，价格面议，如果可以提供具体品种的中国种植基地信息，通过验证齐全且真实的，每个品种可以获得500元信息服务奖励   [更多]

1、P. A. Prajapati and M. M. Patel, “Formulation and in vitro evaluation of atropine sulphate viscous ocular solutions for the mydriatic and cycloplegic effect,” International Journal of Pharmaceutical and Applied Sciences, vol. 1, no. 2, pp. 70–78, 2010. View at Google Scholar 2、D. S. Satya, K. P. Suria, and P. P. Muthu, “Advanced approaches and evaluation of ocular drug delivery system,” American Journal of PharmTech Research, vol. 1, no. 4, pp. 72–92, 2011. View at Google Scholar 3、B. K. Nanjwade, D. B. Sonaje, and F. V. Manvi, “In vitro—in vivo release of ciprofloxacin from ophthalmic formulations,” International Journal of Pharmacy and Biotechnology, vol. 1, no. 1, pp. 23–28, 2011. View at Google Scholar 4、Physicochemical properties and stability of nicorandil By Nagai, Hiroshi; Koizumi, Ikue; Haneda, Masatoshi; Imai, Toshikatsu; Kikuchi, Mineo; Shiba, Motoharu From Iyakuhin Kenkyu (1983), 14(6), 968-79. Language: Japanese, Database: CAPLUS 5、Sobean oil partially hydrogenated 最新德国药典   [更多]

当心血管疾病（心脏病或中风）确诊后，医生会提供治疗建议，但病人的决定是至关重要的。美国心脏协会（AHA）与 以病人为中心的成果研究所（PCORI）合作，网络征集文章。你可以是患者，社区志愿者，家庭成员或任何人，只要你有这方面的亲身经验。根据你的情况来阐述患者的治疗决策是怎样做出的，例如：对寿命的影响，对生活质量的影响，费用，或其他？同时关心过程的完整性，时间，等等。。。 “请于2016年6月9日之前将稿件上传到：https://www.innocentive.com/ar/workspace/challengeDetail?challenge=9933835“ THE CHALLENGE Treatment of heart disease and stroke often requires patients and their families to make many decisions on how to move forward after a cardiac event. Specifically, AHA and PCORI are interested in learning about the “decisional dilemmas” you face – your insights will help guide future research to improve heart health. Based on the input from you and others in the patient and caregiver community, we will identify important concerns and use the perspectives to target research towards what matters most. Despite multiple available treatment options that your physician may describe, you may not always know which option is right/best for you. Tell us about the most difficult decision that you or your family faced when evaluating treatment options for heart disease or stroke. In addition, we would like to understand more about what you considered most important when making this choice or decision. Please pick your top three choices and tell us why they are important to you and your family: Side effects of the treatment Complexity of treatment plan Difficulty in adhering to a treatment Impact on my quality of life Potential to prolong my life Whether the best option for me is selected based on research of people similar to me (personal characteristics such as my age, race and gender) Whether my family history and genetic makeup would influence the effectiveness of a given option Whether a trusted source recommended a specific option The financial impact of the options for me and my family Other:________ Any submission should address the following Submission Requirements: The submission can be from anyone (patient, caregiver, family member, or other)   [更多]